Shopping Cart

Imagion Biosystems Initiates Regulatory Communications for First-in-Human Study

Imagion Biosystems Initiates Regulatory Communications for First-in-Human Study

Imagion Biosystems has filed a Pre-Submission with the U.S. Food and Drug Administration (FDA), the first step is gaining approval to commence its first-in-human study. The communication with the FDA’s Center for Devices and Radiological Health (CDRH) follows from the recent notification that the Company’s MagSense System and Test for staging HER2 breast cancer have been designated as a “Breakthrough Device.”
Read the announcement.

Related Articles

2023 AGM Resolution Overview

Video Transcript: Robert Proulx, Imagion Biosystems’ President & CEO: [00:00:00] On April 24th, we sent out the notice of meeting for our annual general meeting

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.